Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-01
DOI
10.3389/fonc.2021.751271
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
- (2021) Hong-Yue Lai et al. Frontiers in Cell and Developmental Biology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- (2020) Yolanda Augustin et al. PHARMACOLOGY & THERAPEUTICS
- FOXM1 promotes hepatocellular carcinoma progression by regulating KIF4A expression
- (2019) Guohui Hu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling
- (2019) Yujie Li et al. ARCHIVES OF TOXICOLOGY
- Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression
- (2019) Li-Fang Chou et al. Biomolecules
- FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1
- (2018) Na Chai et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
- (2018) K. Lohitesh et al. Cancer Cell International
- Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma
- (2018) Chuan Tian et al. GENE THERAPY
- Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer
- (2018) Maxime Mermod et al. INTERNATIONAL JOURNAL OF CANCER
- Apoptosis: A Target for Anticancer Therapy
- (2018) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis
- (2018) Chaojie Liang et al. OncoTargets and Therapy
- Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
- (2018) Otília Menyhárt et al. Royal Society Open Science
- FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
- (2017) Renata A. Tassi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells
- (2017) N Yang et al. ONCOGENE
- Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer
- (2017) Jing Zhang et al. Recent Patents on Anti-Cancer Drug Discovery
- FoxM1: Repurposing an oncogene as a biomarker
- (2017) Deeptashree Nandi et al. SEMINARS IN CANCER BIOLOGY
- FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas
- (2017) David Milewski et al. PLoS Genetics
- Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells
- (2016) Renyu Lin et al. CANCER LETTERS
- Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular InjuryCLINICAL PERSPECTIVE
- (2016) Xiaojia Huang et al. CIRCULATION
- β-catenin and Kras/Foxm1 signaling pathway are critical to restrict Sox9 in basal cells during pulmonary branching morphogenesis
- (2016) Vladimir Ustiyan et al. DEVELOPMENTAL DYNAMICS
- Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis
- (2016) JIANGUANG JIA et al. Molecular Medicine Reports
- Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1
- (2015) Ji-chao Wei et al. ACTA PHARMACOLOGICA SINICA
- FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance
- (2015) Gabriela Nestal de Moraes et al. CELLULAR SIGNALLING
- Oncogenic Human Papillomavirus 16E7 modulates SUMOylation of FoxM1b
- (2015) Neha Jaiswal et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma
- (2015) Fan-Di Meng WORLD JOURNAL OF GASTROENTEROLOGY
- FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2
- (2015) Yeri Lee et al. PLoS One
- Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth
- (2014) T Chen et al. CANCER GENE THERAPY
- Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo
- (2014) Judong Luo et al. Radiation Oncology
- Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition
- (2014) Michael V. Gormally et al. Nature Communications
- Involvement of FoxM1 in Non-Small Cell Lung Cancer Recurrence
- (2013) Nuo Xu et al. Asian Pacific Journal of Cancer Prevention
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Foxm1 Expression in Prostate Epithelial Cells Is Essential for Prostate Carcinogenesis
- (2013) Yuqi Cai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel
- (2013) Xiaoxiao Li et al. Journal of Translational Medicine
- FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51
- (2012) N. Zhang et al. CLINICAL CANCER RESEARCH
- FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis
- (2011) Nu Zhang et al. CANCER CELL
- FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria
- (2011) Hongcheng Sun et al. CANCER LETTERS
- A Novel FoxM1-Caveolin Signaling Pathway Promotes Pancreatic Cancer Invasion and Metastasis
- (2011) C. Huang et al. CANCER RESEARCH
- FoxM1: A Master Regulator of Tumor Metastasis
- (2011) P. Raychaudhuri et al. CANCER RESEARCH
- Multiple faces of FoxM1 transcription factor
- (2011) Tanya V. Kalin et al. CELL CYCLE
- Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
- (2011) G. Portella et al. CURRENT MEDICINAL CHEMISTRY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- The transcription factor FOXM1 is a cellular target of the natural product thiostrepton
- (2011) Nagaratna S. Hegde et al. Nature Chemistry
- Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro
- (2010) Qi-fei Wu et al. ACTA PHARMACOLOGICA SINICA
- FoxM1 Mediates Resistance to Herceptin and Paclitaxel
- (2010) Janai R. Carr et al. CANCER RESEARCH
- The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells
- (2010) Jin-Jian Lu et al. INVESTIGATIONAL NEW DRUGS
- FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells
- (2010) J. M.-M. Kwok et al. MOLECULAR CANCER RESEARCH
- Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence
- (2010) D. R. Littler et al. NUCLEIC ACIDS RESEARCH
- Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells
- (2010) Tan Weifeng et al. PHYTOMEDICINE
- Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents
- (2009) Devdutt Chaturvedi et al. CHEMICAL SOCIETY REVIEWS
- Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
- (2009) U. B. McGovern et al. MOLECULAR CANCER THERAPEUTICS
- FoxM1 Is a General Target for Proteasome Inhibitors
- (2009) Uppoor G. Bhat et al. PLoS One
- Deletion of Forkhead Box M1 Transcription Factor from Respiratory Epithelial Cells Inhibits Pulmonary Tumorigenesis
- (2009) I-Ching Wang et al. PLoS One
- Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action
- (2008) J. Hou et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation
- (2007) Ikuhiko Nakase et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now